Bessemer Group Inc. bought a new stake in shares of InMode Ltd. (NASDAQ:INMD - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 34,800 shares of the healthcare company's stock, valued at approximately $617,000. Bessemer Group Inc. owned about 0.05% of InMode as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Orion Capital Management LLC bought a new stake in InMode in the fourth quarter worth $65,000. SBI Securities Co. Ltd. bought a new position in shares of InMode during the fourth quarter valued at about $87,000. Farther Finance Advisors LLC increased its holdings in shares of InMode by 26.2% in the fourth quarter. Farther Finance Advisors LLC now owns 5,555 shares of the healthcare company's stock worth $93,000 after buying an additional 1,154 shares during the period. Covestor Ltd lifted its stake in shares of InMode by 13.9% in the 4th quarter. Covestor Ltd now owns 5,936 shares of the healthcare company's stock valued at $99,000 after acquiring an additional 723 shares during the last quarter. Finally, Lazard Asset Management LLC lifted its stake in shares of InMode by 6,128.7% in the 4th quarter. Lazard Asset Management LLC now owns 6,291 shares of the healthcare company's stock valued at $105,000 after acquiring an additional 6,190 shares during the last quarter. Institutional investors own 68.04% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on INMD shares. Barclays reduced their price target on InMode from $29.00 to $24.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 30th. Needham & Company LLC reissued a "hold" rating on shares of InMode in a research note on Monday, April 28th. Baird R W cut shares of InMode from a "strong-buy" rating to a "hold" rating in a report on Monday, April 28th. Jefferies Financial Group lowered their price target on shares of InMode from $16.00 to $15.00 and set a "hold" rating for the company in a report on Monday, April 14th. Finally, UBS Group dropped their price target on shares of InMode from $19.00 to $16.25 and set a "neutral" rating for the company in a research report on Tuesday, April 29th. Seven research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $18.54.
Check Out Our Latest Stock Analysis on INMD
InMode Stock Down 0.4%
Shares of INMD traded down $0.06 during mid-day trading on Thursday, hitting $15.16. 595,953 shares of the company's stock traded hands, compared to its average volume of 1,225,793. The firm has a market capitalization of $957.95 million, a P/E ratio of 6.50 and a beta of 1.95. The business's 50-day moving average price is $14.37 and its 200-day moving average price is $16.32. InMode Ltd. has a 1 year low of $13.14 and a 1 year high of $19.85.
InMode (NASDAQ:INMD - Get Free Report) last issued its quarterly earnings data on Monday, April 28th. The healthcare company reported $0.31 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.45 by ($0.14). InMode had a net margin of 44.79% and a return on equity of 17.17%. The company had revenue of $77.87 million for the quarter, compared to analysts' expectations of $82.21 million. During the same period in the previous year, the firm posted $0.32 earnings per share. The firm's revenue for the quarter was down 3.0% compared to the same quarter last year. Sell-side analysts anticipate that InMode Ltd. will post 1.75 earnings per share for the current fiscal year.
InMode Company Profile
(
Free Report)
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
Featured Stories
Before you consider InMode, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InMode wasn't on the list.
While InMode currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
